Download App

Log in to access Online Inquiry
Company Overview More
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson’s disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer’s disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer’s disease; and dual Aβ-Tau vaccine for the treatment and prevention of Alzheimer’s disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
CEO: Kinney Ph.D., Gene G.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Moomoo > Quotes > PRTA Prothena > Detailed Quotes

PRTA Prothena

26.430-0.650-2.40%
Close 05/23 18:07 ET
26.43000.00%
Post Mkt Price 05/23 16:00 ET
High
27.760
Open
27.340
Turnover
4.63M
Low
26.200
Pre Close
27.080
Volume
173.38K
Market Cap
1.24B
P/E(TTM)
17.50
52wk High
79.749
Shares
46.81M
P/E(Static)
19.15
52wk Low
23.820
Float Cap
624.17M
Bid/Ask %
33.33%
Historical High
79.749
Shs Float
23.62M
Volume Ratio
0.42
Historical Low
5.640
Dividend TTM
--
Div Yield TTM
1200
P/B
2.82
Dividend LFY
--
Div Yield LFY
4540.30%
Turnover Ratio
0.73%
Amplitude
5.76%
Avg Price
26.707
Lot Size
1
Float Cap
624.17M
Bid/Ask %
33.33%
Historical High
79.749
Shs Float
23.62M
Volume Ratio
0.42
Historical Low
5.640
Dividend TTM
--
P/B
2.82
Dividend LFY
--
Turnover Ratio
0.73%
Amplitude
5.76%
Avg Price
26.707
Lot Size
1
Price Forecast

No Data

News

Comment